Literature DB >> 30571233

Angiotensin II Causes Biphasic STAT3 Activation Through TLR4 to Initiate Cardiac Remodeling.

Jibo Han1,2,3, Shiju Ye1,2, Chunpeng Zou4, Taiwei Chen1,2, Jingying Wang1, Jieli Li1, Liqin Jiang3, Jianjiang Xu3, Weijian Huang2, Yi Wang1, Guang Liang1.   

Abstract

Evidence indicates that Ang II (angiotensin II) activates STAT3 (signal transducer and activator of transcription 3) in cardiomyocytes. However, the mechanisms underlying STAT3 activation and downstream responses are not fully known. In this study, we show that Ang II caused biphasic STAT3 activation in cardiomyocytes. A rapid and early activation was mediated by direct association between TLR4 (toll-like receptor-4) and STAT3. This early activation increased IL-6 (interleukin-6) production, which in turn, induced the second STAT3 activation through the IL-6/gp130 (glycoprotein 130)/JAK2 (Janus-family tyrosine kinases 2) pathway, resulting in unregulated expression of genes for cardiac remodeling. Moreover, STAT3 inhibition or TLR4 knockout in mice protected against Ang II-induced hypertrophy, fibrosis, and cardiac functional deficits. Thus, Ang II-induced STAT3 activation in cardiomyocytes was biphasic, providing a sequential induction of IL-6 and myocardial remodeling genes, respectively. This work supports a novel mechanism on STAT3 activation in Ang II-induced cardiac dysfunction and remodeling.

Entities:  

Keywords:  STAT3 protein; angiotensin II; cardiac hypertrophy; interleukin 6; toll-like receptor

Mesh:

Substances:

Year:  2018        PMID: 30571233     DOI: 10.1161/HYPERTENSIONAHA.118.11860

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  17 in total

1.  TLR4 regulates vascular smooth muscle cell proliferation in hypertension via modulation of the NLRP3 inflammasome.

Authors:  Hui-Meng Qi; Qin Cao; Qiang Liu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  Toll-like receptor 4 mutation protects the kidney from Ang-II-induced hypertensive injury.

Authors:  Suravi Majumder; Sathnur Pushpakumar; Subir K Juin; Venkatakrishna R Jala; Utpal Sen
Journal:  Pharmacol Res       Date:  2021-12-09       Impact factor: 7.658

Review 3.  Endothelial-Mesenchymal Transition or Functional Tissue Regeneration - Two Outcomes of Heart Remodeling.

Authors:  B Šalingová; Z Červenák; A Adamičková; N Chomanicová; S Valášková; A Gažová; J Kyselovič
Journal:  Physiol Res       Date:  2021-11-30       Impact factor: 1.881

4.  Omentin inhibits the resistin-induced hypertrophy of H9c2 cardiomyoblasts by inhibiting the TLR4/MyD88/NF-κB signaling pathway.

Authors:  Xiaoliang Yan; Lin Wu; Min Gao; Pengjie Yang; Jinjing Yang; Yongzhi Deng
Journal:  Exp Ther Med       Date:  2022-02-17       Impact factor: 2.447

5.  Silencing of TLR4 Inhibits Atrial Fibrosis and Susceptibility to Atrial Fibrillation via Downregulation of NLRP3-TGF-β in Spontaneously Hypertensive Rats.

Authors:  Chenliang Ge; Yaxin Zhao; Yuming Liang; Yan He
Journal:  Dis Markers       Date:  2022-07-11       Impact factor: 3.464

6.  Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling.

Authors:  Rajvir Singh; Ravinder K Kaundal; Baoyin Zhao; Rihab Bouchareb; Djamel Lebeche
Journal:  Pharmacol Res       Date:  2021-01-29       Impact factor: 7.658

Review 7.  RAS inhibition in resident fibroblast biology.

Authors:  Alexandra M Garvin; Bilal S Khokhar; Michael P Czubryt; Taben M Hale
Journal:  Cell Signal       Date:  2020-12-25       Impact factor: 4.315

8.  A cathelicidin-related antimicrobial peptide suppresses cardiac hypertrophy induced by pressure overload by regulating IGFR1/PI3K/AKT and TLR9/AMPKα.

Authors:  Xiaofang Wang; Linlin Chen; Xiaoyan Zhao; Lili Xiao; Shanting Yi; Yawei Kong; Yan Jiang; Jinying Zhang
Journal:  Cell Death Dis       Date:  2020-02-06       Impact factor: 8.469

9.  AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells.

Authors:  Xuemei Chen; Xuejiao Zhang; Jiajun Xu; Yiqing Zhao; Jiachun Bao; Zhanxiong Zheng; Jibo Han
Journal:  Drug Des Devel Ther       Date:  2020-02-26       Impact factor: 4.162

10.  Angiotensin II blockers improve cardiac coronary flow under hemodynamic pressure overload.

Authors:  Wei-Ting Chang; Sudeshna Fisch; Seema Dangwal; Michael Chen; Susan Cheng; Zhih-Cherng Chen; Ronglih Liao
Journal:  Hypertens Res       Date:  2021-02-10       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.